Northeast Financial Consultants’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $25.2M | Sell |
1,040,851
-111,079
| -10% | -$2.59M | 1.03% | 22 |
|
|
2025
Q1 | $29.2M | Sell |
1,151,930
-4,367
| -0.4% | -$114K | 1.29% | 19 |
|
|
2024
Q4 | $30.7M | Sell |
1,156,297
-51,697
| -4% | -$1.4M | 1.29% | 20 |
|
|
2024
Q3 | $35M | Buy |
1,207,994
+11,226
| +0.9% | +$327K | 1.53% | 15 |
|
|
2024
Q2 | $33.5M | Sell |
1,196,768
-46,391
| -4% | -$1.28M | 1.54% | 17 |
|
|
2024
Q1 | $34.5M | Sell |
1,243,159
-1,413,451
| -53% | -$39.2M | 1.69% | 15 |
|
|
2023
Q4 | $76.5M | Buy |
2,656,610
+206,107
| +8% | +$6.23M | 4.23% | 5 |
|
|
2023
Q3 | $81.3M | Sell |
2,450,503
-191,848
| -7% | -$6.78M | 5.09% | 4 |
|
|
2023
Q2 | $96.9M | Sell |
2,642,351
-514
| -0% | -$20K | 5.95% | 2 |
|
|
2023
Q1 | $108M | Buy |
2,642,865
+694,566
| +36% | +$30M | 6.9% | 2 |
|
|
2022
Q4 | $99.8M | Buy |
1,948,299
+46,227
| +2% | +$2.22M | 6.74% | 2 |
|
|
2022
Q3 | $83.2M | Sell |
1,902,072
-56,350
| -3% | -$2.74M | 6.1% | 3 |
|
|
2022
Q2 | $103M | Sell |
1,958,422
-13,346
| -0.7% | -$680K | 7.16% | 2 |
|
|
2022
Q1 | $102M | Buy |
1,971,768
+383,242
| +24% | +$19.9M | 5.91% | 2 |
|
|
2021
Q4 | $93.8M | Sell |
1,588,526
-13,194
| -0.8% | -$654K | 5.66% | 2 |
|
|
2021
Q3 | $68.9M | Sell |
1,601,720
-6,745
| -0.4% | -$299K | 4.6% | 3 |
|
|
2021
Q2 | $63M | Buy |
1,608,465
+307,977
| +24% | +$12M | 4.24% | 2 |
|
|
2021
Q1 | $47.1M | Buy |
1,300,488
+8,289
| +0.6% | +$294K | 3.6% | 6 |
|
|
2020
Q4 | $47.6M | Sell |
1,292,199
-1,692,277
| -57% | -$62.1M | 3.94% | 3 |
|
|
2020
Q3 | $104M | Buy |
2,984,476
+66,823
| +2% | +$2.34M | 9.39% | 2 |
|
|
2020
Q2 | $91.5M | Buy |
2,917,653
+19,803
| +0.7% | +$673K | 8.79% | 2 |
|
|
2020
Q1 | $89.7M | Buy |
2,897,850
+344,858
| +14% | +$11.8M | 10.17% | 2 |
|
|
2019
Q4 | $94.9M | Buy |
2,552,992
+845,226
| +49% | +$30.1M | 8.48% | 2 |
|
|
2019
Q3 | $58.2M | Sell |
1,707,766
-817,499
| -32% | -$29.7M | 5.93% | 2 |
|
|
2019
Q2 | $104M | Buy |
2,525,265
+2,242
| +0.1% | +$89K | 10.65% | 1 |
|
|
2019
Q1 | $102M | Sell |
2,523,023
-23,810
| -0.9% | -$954K | 11.29% | 1 |
|
|
2018
Q4 | $105M | Buy |
2,546,833
+2,143,840
| +532% | +$89M | 14.68% | 1 |
|
|
2018
Q3 | $16.8M | Sell |
402,993
-994,313
| -71% | -$38.3M | 4.63% | 5 |
|
|
2018
Q2 | $48.1M | Sell |
1,397,306
-948
| -0.1% | -$32.4K | 14.82% | 1 |
|
|
2018
Q1 | $47.1M | Sell |
1,398,254
-4,627
| -0.3% | -$159K | 15.82% | 1 |
|
|
2017
Q4 | $48.2M | Buy |
1,402,881
+19,337
| +1% | +$659K | 16.02% | 1 |
|
|
2017
Q3 | $46.9M | Sell |
1,383,544
-119,238
| -8% | -$3.83M | 17.17% | 1 |
|
|
2017
Q2 | $47.9M | Sell |
1,502,782
-69,036
| -4% | -$2.18M | 18.87% | 1 |
|
|
2017
Q1 | $51M | Sell |
1,571,818
-58,839
| -4% | -$1.86M | 21.31% | 1 |
|
|
2016
Q4 | $50.3M | Sell |
1,630,657
-8,708
| -0.5% | -$266K | 22.44% | 1 |
|
|
2016
Q3 | $52.7M | Buy |
1,639,365
+49,566
| +3% | +$1.66M | 22.24% | 1 |
|
|
2016
Q2 | $60.1M | Buy |
1,589,799
+4,098
| +0.3% | +$131K | 26.73% | 1 |
|
|
2016
Q1 | $44.6M | Buy |
1,585,701
+104,439
| +7% | +$2.98M | 23.39% | 1 |
|
|
2015
Q4 | $45.4M | Sell |
1,481,262
-27,261
| -2% | -$858K | 23.54% | 1 |
|
|
2015
Q3 | $45M | Buy |
1,508,523
+11,363
| +0.8% | +$364K | 22.84% | 1 |
|
|
2015
Q2 | $47.6M | Buy |
1,497,160
+7,695
| +0.5% | +$251K | 21.33% | 1 |
|
|
2015
Q1 | $49.2M | Buy |
1,489,465
+111,841
| +8% | +$3.56M | 22.36% | 1 |
|
|
2014
Q4 | $40.7M | Buy |
1,377,624
+5,341
| +0.4% | +$153K | 21.45% | 1 |
|
|
2014
Q3 | $38.5M | Buy |
1,372,283
+107,555
| +9% | +$3.02M | 21.13% | 1 |
|
|
2014
Q2 | $35.6M | Sell |
1,264,728
-1,316
| -0.1% | -$37.5K | 20.17% | 1 |
|
|
2014
Q1 | $38.6M | Buy |
1,266,044
+6,847
| +0.5% | +$204K | 22.71% | 1 |
|
|
2013
Q4 | $36.6M | Buy |
+1,259,197
| New | +$36.6M | 24.48% | 1 |
|
Other funds holding PFE
Northeast Financial Consultants's PFE Position: Q2 2025 in Review
Northeast Financial Consultants reduced its Pfizer (PFE) stake by 9.6% in Q2 2025, selling an estimated $2.59M and leaving 1,040,851 shares worth $25.2M. The position accounts for 1.03% of the portfolio, ranked #22.
Northeast Financial Consultants first reported a position in PFE in Q4 2013 and has held it in 47 quarters since. The position peaked at $108M in Q1 2023. 2,809 funds tracked by Wall St. Rank hold PFE as of Q2 2025.
- Northeast Financial Consultants held 1,040,851 shares of Pfizer worth $25.2M as of Q2 2025.
- Northeast Financial Consultants sold 111,079 Pfizer shares in Q2 2025, an estimated $2.59M.
- Pfizer made up 1.03% of Northeast Financial Consultants's portfolio in Q2 2025, its #22 holding.
- Northeast Financial Consultants first reported a position in Pfizer in Q4 2013 and has held it in 47 quarters since.
- Northeast Financial Consultants's Pfizer position peaked at $108M in Q1 2023.
- 2,809 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.
Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.